Chemical-structure (Chemical Structure)
Memantine Hydrochloride
Product Images NDC 47335-031
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Memantine Hydrochloride (NDC 47335-031). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Sun Pharmaceutical Industries, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure1 (Figure1)
This is a graph that shows the time course of change from baseline in SIB score for patients completing 24 weeks of treatment with either Memantine Hydrochloride Extended-Release Capsules 28 mg/ACHEI or Placebo/ACHEI. The graph shows mean (= SEM) change from baseline in SIB score for clinical improvement or critical decline.*
Figure2 (Figure2)
The text describes a graph (Figure 2) showing the percentage of patients who completed a 24 week double-blind treatment with changes from baseline in SIB scores. The graph shows the cumulative percentage of patients and has values on the x-axis ranging from -20 to 50, with 10-unit increments. The exact nature of the treatment and SIB scores is not provided.*
Figure3 (Figure3)
The image shows a graph of the time course of the CIBIC-Plus score for patients completing 24 weeks of treatment. The graph is related to the improvement, decline, and clinical aspects of patients treated with Memantine Hydrochloride Extended-Release capsules 28mg, compared to a placebo/ACHEI treatment. There is no other available information provided in the text.*
Figure4 (Figure4)
This is a figure that shows the distribution of CIBIC-Plus ratings at week 24 for patients taking either memantine hydrochloride extended-release capsules or a placebo along with an AChE inhibitor. The figure includes a graph with different categories of improvement and worsening, but there is no additional information provided.*
Spl-menatine-14-mg (Spl Menatine 14 mg)
This appears to be a label of Memantine Hydrochloride Extended-release capsules, with information for the pharmacist to dispense with a separate patient information leaflet. The NDC number and dosage form are also provided. However, some of the characters are garbled or missing, making the text difficult to fully comprehend.*
Spl-menatine-21-mg (Spl Menatine 21 mg)
This is a prescription drug labeled NDC 47335-033-83. It is an extended-release capsule containing Memantine Hydrochloride and is meant to be taken once daily. The label instructs pharmacists to dispense without the patient information leaflet, which is provided separately. The package contains 30 capsules. The rest of the text is product codes and information for labeling.*
Spl-menatine-28-mg (Spl Menatine 28 mg)
This appears to be a medication label for a drug called Memantine Hydrochloride Extended-Release Capsules, with dosage information of "30 capsules". The label is instructing the pharmacist to dispense it without a patient information leaflet, which will be provided separately. The given number "NOC 47335.034.83" and codes "DNH/DRUGS/NH/138" and "PGLB0995" may be related to the specific manufacture or distribution of the product.*
Spl-menatine-7-mg (Spl Menatine 7 mg)
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
